Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

DiSilvestro, Paul; Banerjee, Susana; Colombo, Nicoletta; Scambia, Giovanni; Kim, Byoung‐Gie; Oaknin, Ana; Friedländer, Michael; Lisyanskaya, Alla; Floquet, Anne; Léary, Alexandra; S. Sonke, Gabe; Gourley, Charlie; M. Oza, Amit; González-Martı́n, Antonio; Aghajanian, Carol; H. Bradley, William; Mathews, Cara; F. Liu, Joyce; McNamara, John; Lowe, Elizabeth; Ah-See, Mei-Lin; N. Moore, Kathleen; behalf of the SOLO1 Investigators, on

doi:10.1200/jco.22.01549

Public

Overall Survival With Maintenance Olaparib at a 7-Year Follow-Up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial

Published in Journal of Clinical Oncology • Sep 9, 2022

Authors:

Paul DiSilvestro

Susana Banerjee

Nicoletta Colombo

Abstract

PURPOSE In SOLO1/GOG 3004 (ClinicalTrials.gov identifier: NCT01844986 ), maintenance therapy with the poly(ADP-ribose) polymerase inhibitor olaparib provided a sustained progression-free survival benefit in patients with newly diagnosed advanced ovarian cancer and a BRCA1 and/or BRCA2 (BRCA) mutatio...

Subject

Olaparib

Medicine

PARP inhibitor

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!